


ADVERTISEMENT

Traumatic brain injury



THE LANCET
Neurology

[Home](#) [Journals](#) [Specialties](#) [The Lancet Clinic](#) [Global Health](#) [Multimedia](#) [Campaigns](#) [More](#) [Information for](#)

Submit a Review

[Previous](#)

[Comment](#)

[Extended-release naltrexone: good but not a panacea](#)

[Next](#)

[Editorial](#)

[India—a tale of one country, but stories of many states](#)

THE LANCET



[Login](#) | [Register](#) | [Claim Your Subscription](#) | [Subscribe](#)

[Online First](#) [Current Issue](#) [All Issues](#) [Special Issues](#) [Multimedia](#) [Information for Authors](#)

[All Content](#)

[Search](#) [Advanced Search](#)

< Previous Article



Online First

Next Article >

Access this article on [ScienceDirect](#) ▶

Articles

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Dr Joshua D Lee, MD  , Edward V Nunes Jr, MD, Patricia Novo, MPH, Ken Bachrach, PhD, Genie L Bailey, MD, Snehal Bhatt, MD, Sarah Farkas, MA, Marc Fishman, MD, Phoebe Gauthier, MPH, Candace C Hodgkins, PhD, Jacquie King, MS, Robert Lindblad, MD, David Liu, MD, Abigail G Matthews, PhD, Jeanine May, PhD, K Michelle Peavy, PhD, Stephen Ross, MD, Dagmar Salazar, MS, Paul Schkolnik, PhD, Dikla Shmueli-Blumberg, PhD, Don Stablein, PhD, Geetha Subramaniam, MD, John Rotrosen, MD

Published: 14 November 2017

[PlumX Metrics](#)



DOI: [http://dx.doi.org/10.1016/S0140-6736\(17\)32812-X](http://dx.doi.org/10.1016/S0140-6736(17)32812-X) |



Article Info

Summary

Full Text

Tables and Figures

References

Supplementary Material

Summary

Background

Extended-release naltrexone (XR-NTX), an opioid antagonist, and sublingual buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are pharmacologically and conceptually distinct interventions to prevent opioid relapse. We aimed to estimate the difference in opioid relapse-free survival between XR-NTX and BUP-NX.

Methods

Article Options

 PDF (1005 KB)


 Download Images(.ppt)

 Email Article

 Add to My Reading List

 Export Citation

 Create Citation Alert

 Cited by in Scopus (0)

Linked Articles

COMMENT

Extended-release naltrexone: good but not a panacea

COMMENT

Medications for opioid use disorder: bridging the gap in care

We initiated this 24 week, open-label, randomised controlled, comparative effectiveness trial at eight US community-based inpatient services and followed up participants as outpatients. Participants were 18 years or older, had Diagnostic and Statistical Manual of Mental Disorders-5 opioid use disorder, and had used non-prescribed opioids in the past 30 days. We stratified participants by treatment site and opioid use severity and used a web-based permuted block design with random equally weighted block sizes of four and six for randomisation (1:1) to receive XR-NTX or BUP-NX. XR-NTX was monthly intramuscular injections (Vivitrol; Alkermes) and BUP-NX was daily self-administered buprenorphine-naloxone sublingual film (Suboxone; Indivior). The primary outcome was opioid relapse-free survival during 24 weeks of outpatient treatment. Relapse was 4 consecutive weeks of any non-study opioid use by urine toxicology or self-report, or 7 consecutive days of self-reported use. This trial is registered with [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02032433), NCT02032433.

Findings

Between Jan 30, 2014, and May 25, 2016, we randomly assigned 570 participants to receive XR-NTX (n=283) or BUP-NX (n=287). The last follow-up visit was Jan 31, 2017. As expected, XR-NTX had a substantial induction hurdle: fewer participants successfully initiated XR-NTX (204 [72%] of 283) than BUP-NX (270 [94%] of 287; $p < 0.0001$). Among all participants who were randomly assigned (intention-to-treat population, n=570) 24 week relapse events were greater for XR-NTX (185 [65%] of 283) than for BUP-NX (163 [57%] of 287; hazard ratio [HR] 1.36, 95% CI 1.10–1.68), most or all of this difference accounted for by early relapse in nearly all (70 [89%] of 79) XR-NTX induction failures. Among participants successfully inducted (per-protocol population, n=474), 24 week relapse events were similar across study groups ($p=0.44$). Opioid-negative urine samples ($p < 0.0001$) and opioid-abstinent days ($p < 0.0001$) favoured BUP-NX compared with XR-NTX among the intention-to-treat population, but were similar across study groups among the per-protocol population. Self-reported opioid craving was initially less with XR-NTX than with BUP-NX ($p=0.0012$), then converged by week 24 ($p=0.20$). With the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse events including overdose did not differ between treatment groups. Five fatal overdoses occurred (two in the XR-NTX group and three in the BUP-NX group).

Interpretation

In this population it is more difficult to initiate patients to XR-NTX than BUP-NX, and this negatively affected overall relapse. However, once initiated, both medications were equally safe and effective. Future work should focus on facilitating induction to XR-NTX and on

Popular Articles

Most Read

Most Cited

Most read in *The Lancet* within the past 30 days.

ARTICLES

Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
Vol. 390, No. 10107
Published: August 29, 2017

[Open Access](#)

ARTICLES

Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial

Published: November 20, 2017

[Open Access](#)

ARTICLES

Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients
Published: November 7, 2017

[Open Access](#)

improving treatment retention for both medications.

Funding

NIDA Clinical Trials Network.

To read this article in full you will need to make a payment

Already registered? Please login.

[Login to existing account](#)

[Forgot password?](#)

Register

[Create a new account](#)

The Lancet Choice

Access any 5 articles from The Lancet family of journals

- Full text and PDF access to 5 paywall articles of your choice
- Valid for 365 days from date of purchase
- [Find out more about The Lancet Choice](#)

Payment Options

- **Purchase this article for \$31.50 USD**
 - Online access for 24 hours
 - PDF version can be downloaded as your permanent record

Subscribe to The Lancet

[Purchase a subscription](#) to gain access to this and all other articles in this journal.

Options include:

- [Personal online only subscription](#)

Institutional Access

[Visit ScienceDirect](#) to see if you have access via your institution.

Already a print subscriber?

[Claim online access](#)

Have a free trial code?

[Activate your free trial](#)

ARTICLES

[Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults](#)

Published: October 10, 2017

[Open Access](#)

ARTICLES

[Percutaneous coronary intervention in stable angina \(ORBITA\): a double-blind, randomised controlled trial](#)

Published: November 2, 2017

The Lancet Choice



The Lancet Choice is a new payment option that gives you the freedom and flexibility to access any 5 premium articles of your choice from across *The Lancet* family of journals - all for a one-off payment of \$49.00 USD.

Simply purchase your Lancet Choice pass from the Summary or Full Text page of an article you wish to access. This will count as the first of 5 article credits, or 'Allowances', and you can use your 4 remaining Allowances to access other articles from any of *The Lancet* journals.

[Find out more about The Lancet Choice](#)

The Lancet Journals

The Lancet
The Lancet Child & Adolescent Health
The Lancet Diabetes & Endocrinology
The Lancet Gastroenterology & Hepatology

The Lancet HIV
The Lancet Infectious Diseases
The Lancet Neurology
The Lancet Oncology
The Lancet Planetary Health
The Lancet Psychiatry
The Lancet Public Health

Information & Support

About Us
Information for Authors
Information for Readers
The Lancet Careers
Customer Service

Subscription

Your Account
Subscription Options
Existing Print Subscribers

[The Lancet Global Health](#)
[The Lancet Haematology](#)

[The Lancet Respiratory Medicine](#)
[EBioMedicine](#)

[Contact Us](#)
[Privacy Policy](#)
[Terms and Conditions](#)

Copyright © 2017 Elsevier Limited except certain content provided by third parties.

The Lancet is a trade mark of Elsevier Limited.

The Lancet.com website is operated by Elsevier Inc. The content on this site is intended for health professionals.

Cookies are set by this site. To decline them or learn more, visit our [Cookies page](#).

The Lancet demonstrates its commitment to accessibility by enabling access and optimising the experience for individuals with disabilities and impairments.